Ectolysin P128, GangaGen’s lead molecule is a chimeric recombinant anti-staphylococcal protein that targets both coagulase positive and coagulase negative Staphylococci.
P128 has a novel mechanism of action and rapidly kills Staphylococci.
It is proven to be very effective both in vitro & in vivo against multidrug resistant pathogens like Methicillin Resistant Staphylococcus aureus (MRSA), Vancomycin Resistant Staphylococcus aureus (VRSA) and Daptomycin Resistant Staphylococcus aureus (DRSA). GangaGen has completed Phase I/IIA studies with P128 for ‘nasal decontamination' of S. aureus from human nares.
GangaGen has used PATP to discover and engineer novel ectolysins suitable for multiple applications.